Answers are grounded in this paper and cite their sources.
Evaluates a contrast agent detecting β-hexosaminidase A activity, suggesting new applications in cancer imaging.
We report the design, synthesis, and evaluation of HexA-Gd, a bioresponsive magnetic resonance imaging (MRI) contrast agent for the selective detection of β-hexosaminidase A (Hex-A) activity. The probe employs a self-immolative linker strategy that modulates Gd(III) coordination and T1 relaxivity in response to enzymatic activation. In vitro relaxometric analyses in phosphate-buffered saline (PBS, pH 7.4, 37 °C, 1.4 T) showed that Hex-A-Gd exhibits a low longitudinal relaxivity (r1 = 3.06 mM−1 s−1) in its pristine form, which increases to 3.78 mM−1 s−1, following enzymatic conversion by Hex-A. Time-course measurements confirmed rapid activation kinetics, with significant T1 shortening within 20 min of enzyme exposure. High-field MRI phantom imaging at 7 T further validated the relaxivity enhancement, yielding r1 = 5.06 mM−1 s−1 and r2 = 7.67 mM−1 s−1 at 25 °C. 1H NMRD profiling revealed the underlying molecular mechanism, highlighting q-modulated relaxivity changes compared to a nonresponsive control probe (NDO3A-Gd). Cell-based studies in SW480 colorectal cancer cells demonstrated low cytotoxicity and significant probe uptake relative to the control, indicating efficient internalization in a disease-relevant context. Collectively, these findings establish HexA-Gd as a promising platform for noninvasive MRI-based imaging of Hex-A activity in cancer and lysosomal storage disorders.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: